---
title: "MRAI: Q2 2026 revenue fell 10.5% to $4.2M, with a $4.6M net loss and ongoing liquidity concerns"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295842835.md"
description: "Revenue declined 10.5% year-over-year in Q2 2026 to $4.2M, with a net loss of $4.6M and negative cash flow from operations. The company faces substantial going concern risks and is seeking additional capital, while recent financing and amended debt agreements provide temporary relief.Original document: Marpai, Inc. [MRAI] SEC 10-Q Quarterly Report — Aug. 20 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-13T20:31:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295842835.md)
  - [en](https://longbridge.com/en/news/295842835.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295842835.md)
generator: "portal-rs"
---

# MRAI: Q2 2026 revenue fell 10.5% to $4.2M, with a $4.6M net loss and ongoing liquidity concerns

Revenue declined 10.5% year-over-year in Q2 2026 to $4.2M, with a net loss of $4.6M and negative cash flow from operations. The company faces substantial going concern risks and is seeking additional capital, while recent financing and amended debt agreements provide temporary relief.

Original document: Marpai, Inc. \[MRAI\] SEC 10-Q Quarterly Report — Aug. 20 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [MRAI.US](https://longbridge.com/en/quote/MRAI.US.md)

## Related News & Research

- [Claritev expands Marpai partnership to add pre- and post-payment claims integrity services](https://longbridge.com/en/news/296110570.md)
- [INVEST: Revenue and profit dropped sharply in H1 2026, with 2026 outlook remaining subdued](https://longbridge.com/en/news/296439091.md)
- [Bio-Techne declares Q3 2026 distribution of R$ 0.01 per unit, payable Sept. 10](https://longbridge.com/en/news/296357843.md)
- [Kreditbanken posts 2026 half-year report release](https://longbridge.com/en/news/296349936.md)
- [EGTX: Q2 2026 revenue up 23% YoY; U.S. Emcitate launch expected Q4 2026 pending FDA approval](https://longbridge.com/en/news/296636890.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**